In conclusion, our results underscore the importance of incorporating immune monitoring with CD4+ T cell count and mHLA-DR into the prognostic evaluation of severe COVID-19 patients upon a full dexamethasone treatment course. This evidence concerns the gene CD4 and COVID-19.